STAR-0215, an investigational therapy to prevent swelling attacks in people with hereditary angioedema (HAE), rapidly and durably suppressed the…
Articles by Steve Bryson, PhD
Treatment with sebetralstat, an investigational and oral on-demand therapy, resulted in rapid relief for both abdominal and peripheral attacks in…
The one-year Phase 3 SPRING study evaluating the safety, efficacy, and pharmacological properties of Takhzyro (lanadelumab) in children with…
CSL Plasma has donated $125,000 to the American Red Cross to support recovery and relief efforts following disasters…
Enrollment is open for the open-label, Phase 1/2 HAERMONY trial to evaluate the safety and effectiveness of BMN 331, an…
KVD900, an investigational on-demand therapy for hereditary angioedema (HAE), rapidly and nearly completely suppressed kallikrein and was generally…
KalVista Pharmaceuticals is planning to launch a Phase 3 trial of KVD900, an investigational oral and on-demand treatment…
Orladeyo (berotralstat) reduced the frequency of swelling attacks in people with hereditary angioedema (HAE) and improved their quality…
Astria Therapeutics is the new name of the company that’s developing STAR-0215, an investigational kallikrein-inhibitor previously known as QLS-215,…
Takhzyro (lanadelumab) safely and markedly reduced the frequency of swelling attacks in people with hereditary angioedema (HAE) over…